Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Revive Therapeutics Ltd (RVV.CN)

Revive Therapeutics Ltd (RVV.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 90,289
  • Shares Outstanding, K 319,609
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,119 K
  • 60-Month Beta -1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.29
Trade RVV.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings -0.01 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.215 +27.91%
on 05/13/22
0.435 -36.78%
on 04/19/22
-0.035 (-11.29%)
since 04/14/22
3-Month
0.160 +71.88%
on 04/07/22
0.435 -36.78%
on 04/19/22
+0.020 (+7.84%)
since 02/17/22
52-Week
0.160 +71.88%
on 04/07/22
0.650 -57.69%
on 07/05/21
-0.165 (-37.50%)
since 05/17/21

Most Recent Stories

More News
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.275 (-2.48%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.2200 (unch)
RVV.CN : 0.275 (-2.48%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.2200 (unch)
RVV.CN : 0.275 (-2.48%)
Stocks in play: Revive Therapeutics Ltd

Announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, ...

RVV.CN : 0.275 (-2.48%)
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.2200 (unch)
RVV.CN : 0.275 (-2.48%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.2200 (unch)
RVV.CN : 0.275 (-2.48%)
Stocks in play: Revive Therapeutics Ltd.

Provided an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial ( NCT04504734 ...

RVV.CN : 0.275 (-2.48%)
Top COVID-19 Treatment Stocks Investors Should Consider

The coronavirus isn’t gone just yet. China just imposed new lockdowns in Shanghai, as the city records some of its highest numbers of new COVID-19 cases. Italy just reported another 30,710 cases on...

PFE : 51.34 (+1.32%)
MRNA : 142.28 (+4.42%)
JNJ : 178.82 (+0.42%)
MRK : 93.00 (+0.74%)
RVVTF : 0.2200 (unch)
RVV.CN : 0.275 (-2.48%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international...

RVV.CN : 0.275 (-2.48%)
RVVTF : 0.2200 (unch)
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.2200 (unch)
RVV.CN : 0.275 (-2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.396
2nd Resistance Point 0.351
1st Resistance Point 0.316
Last Price 0.275
1st Support Level 0.236
2nd Support Level 0.191
3rd Support Level 0.156

See More

52-Week High 0.650
Fibonacci 61.8% 0.463
Fibonacci 50% 0.405
Fibonacci 38.2% 0.347
Last Price 0.275
52-Week Low 0.160

See More

Business Summary

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar